NeuroPace (Nasdaq:NPCE) announced today that it appointed Brett Wingeier as its new VP of R&D and Katie Keller as VP of marketing.

NeuroPace（纳斯达克：NPCE）今天宣布，任命布雷特·温吉尔（BrettWingeier）为其新的研发副总裁，凯蒂·凯勒（KatieKeller）为营销副总裁。

Both appointments made by the maker of the FDA-approved RNS system for treating epilepsy go into effect immediately.

FDA批准的用于治疗癫痫的RNS系统制造商做出的两项任命立即生效。

Wingeier’s experience includes a stint as co-founder, CTO and CEO of Magnus Medical, another neurostimulation company. Keller, meanwhile, led global commercial marketing for Boston Scientific’s deep brain stimulation (DBS) franchise.

Wingeier的经历包括担任另一家神经刺激公司Magnus Medical的联合创始人、首席技术官和首席执行官。与此同时，凯勒（Keller）领导波士顿科学公司（Boston Scientific）的深部大脑刺激（DBS）特许经营权的全球商业营销。

“We are excited to welcome Katie and Brett to our team. Katie brings an understanding of the neurostimulation market and expertise in market development through her tenure at Boston Scientific and leading its DBS commercial marketing function. I’m confident that through her leadership our market development programs and plans will move to the next level as we look to close the treatment gap by driving broader adoption and utilization of RNS therapy,” said Joel Becker, CEO of NeuroPace.

NeuroPace首席执行官乔尔·贝克尔（Joel Becker）表示：“我们很高兴欢迎凯蒂（Katie）和布雷特（Brett）加入我们的团队。凯蒂（Katie）在波士顿科学（Boston Scientific）任职期间，并领导其DBS商业营销职能，从而对神经刺激市场和市场开发专业知识有了深入的了解。我相信，通过她的领导，我们的市场开发计划和计划将提高到一个新的水平，因为我们希望通过推动RNS疗法的广泛采用和利用来缩小治疗差距。”。

“Brett is a proven innovator and developer of advanced medical devices, which includes our RNS technology. His extensive knowledge of the RNS System and epilepsy will position him to help advance our strategy to expand the capabilities of the RNS System through our technology development plans and pipeline.”.

“布雷特是先进医疗设备（包括我们的RNS技术）的公认创新者和开发者。他对RNS系统和癫痫病的广泛知识将使他能够通过我们的技术开发计划和管道帮助推进我们的战略，以扩大RNS系统的能力。”。

More about the new VPs at NeuroPace

有关NeuroPace新VPs的更多信息

Keller offers a track record of success in medical device marketing and commercial roles, according to a news release. Most recently, she led the global commercial marketing function for the Boston Scientific DBS franchise, but she also spent time in leadership roles within a number of device markets.

据一份新闻稿称，凯勒在医疗器械营销和商业角色方面取得了成功。最近，她领导了波士顿科学星展（Boston Scientific DBS）特许经营的全球商业营销职能，但她也曾在多个设备市场担任领导角色。

Those include interventional cardiology, cardiac physiology and cardiac rhythm management..

。。

“I am excited to join NeuroPace and look forward to working with the team on expanding access to the Company’s life changing RNS therapy through indication expansion and increased awareness with both patients and clinicians,” said Keller.

Keller说：“我很高兴加入NeuroPace，并期待着与团队合作，通过适应症扩展和提高患者和临床医生的认识，扩大使用该公司改变生命的RNS疗法的机会。”。

Wingeier has more than 20 years of experience across neurotech, biomedical engineering and entrepreneurship. That includes contributing to the development of the NeuroPace RNS system as a principal engineer from 2001 to 2013. Most recently, he served as CEO, CTO and co-founder of Magnus Medical, helping to gain FDA clearance for a depression treatment.

。这包括从2001年到2013年作为首席工程师为NeuroPace RNS系统的开发做出贡献。最近，他担任Magnus Medical的首席执行官、首席技术官和联合创始人，帮助获得FDA批准用于抑郁症治疗。

Before that, he also served in the same positions at Halo Neuroscience, another neuromodulation company..

在此之前，他还在另一家神经调节公司Halo Neuroscience担任相同的职位。。

“I am excited to rejoin NeuroPace at such an exciting time for the company and for the RNS system,” said Wingeier. “The unique monitoring and analysis capabilities of the RNS System have provided us with an unparalleled dataset. I look forward to working with the team and our customers to further evolve these capabilities and translate these data into enhanced ease of use, greater efficiency, and clinical insights that continue to transform the lives of people living with epilepsy.”.

Wingeier说：“在公司和RNS系统如此激动人心的时刻，我很高兴再次加入NeuroPace。”。“RNS系统独特的监测和分析功能为我们提供了无与伦比的数据集。我期待着与团队和客户合作，进一步发展这些功能，并将这些数据转化为增强的易用性，更高的效率和临床见解，继续改变癫痫患者的生活。”。